Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | NOS3 | P29474 | 1/20 | 0.31 |
| ▸ | NOS1 | P29475 | 1/20 | 0.31 |
| ▸ | NOS2 | P35228 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1843462 | 0.99 | NOS3 (0.33) | TSHRNOS3NOS1NOS2 | |
| Hydrochloric Acid SCHEMBL4252036 | 0.94 | NOS3 (0.33) | NOS3NOS1NOS2 | |
| SCHEMBL5642094 | 0.85 | TSHR (0.38) | TSHRNOS3NOS1NOS2 | |
| SCHEMBL6267175 | 0.81 | NOS3 (0.30) | NOS3NOS1NOS2 | |
| Hydrochloric Acid SCHEMBL2732807 | 0.80 | NOS3 (0.32) | NOS3NOS1NOS2 | |
| Cindunistat SCHEMBL119959 | 0.79 | NOS1 (0.49) | TSHRNOS3NOS1NOS2 | |
| Cindunistat SCHEMBL14572932 | 0.79 | NOS1 (0.49) | TSHRNOS3NOS1NOS2 | |
| Cindunistat SCHEMBL5644203 | 0.79 | NOS1 (0.49) | TSHRNOS3NOS1NOS2 | |
| Cindunistat SCHEMBL1842090 | 0.78 | NOS1 (0.43) | TSHRNOS3NOS1NOS2 | |
| Cindunistat SCHEMBL6313297 | 0.78 | NOS1 (0.43) | TSHRNOS3NOS1NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040209956-A1 | S-[2-[(1-Iminoethyl)amino]ethyl]-2-methyl-L-cysteine maleate form II crystalline salt | BROSTROM LYLE (US) | 2004-10-21 | — | — | US | claimed |
| US-20040204488-A1 | S-[2-[(1-Iminoethyl)amino]ethyl]-2-methyl-L-cysteine maleate crystalline salt | PHARMACIA CORPORATION | 2004-10-14 | — | — | US | claimed |
| EP-1603872-B1 | S-[2-[(1-IMINOETHYL)AMINO]ETHYL]-2-METHYL-L-CYSTEINE MALEATE HYDROCHLORIDE CRYSTALLINE SALT | PHARMACIA CORP (US) | 2011-05-18 | — | — | EP | disclosed |
| US-7767850-B2 | S-[2-[(1-iminoethy)amino]ethyl]-2-methyl-L-cysteine maleate hydrochloride crystalline salt | PFIZER INC. (US) | 2010-08-03 | — | — | US | disclosed |
| US-20090215891-A1 | S-[2-[(1-lminoethy)Amino]Ethyl]-2-Methyl-L-Cysteine Maleate Hydrochloride Crystalline Salt | PFIZER, INC. (US) | 2009-08-27 | — | — | US | disclosed |
| CN-100460387-C | S-[2-[(1-iminoethyl)amino]ethyl]-2-methyl-l-cysteine maleate hydrochloride crystalline salt | PHARMACIA CORP (US) | 2009-02-11 | — | — | CN | disclosed |
| CN-1787993-A | S-[2-[(1-iminoethyl)amino]ethyl]-2-methyl-l-cysteine maleate hydrochloride crystalline salt | PHARMACIA CORP (US) | 2006-06-14 | — | — | CN | disclosed |
| EP-1603871-A1 | S-[2-[(I-IMINOETHYL)AMINO]ETHYL]-2-METHYL-L-CYSTEINE MALEATE CRYSTALLINE SALT | Pharmacia Corporation (US) | 2005-12-14 | — | — | EP | disclosed |
| US-20050038120-A1 | S-[2-[(1-Iminoethyl)amino]ethyl]-2-methyl-L-cysteine maleate hydrochloride crystalline salt | BROSTROM LYLE (US) | 2005-02-17 | — | — | US | disclosed |
| US-20040209956-A1 | S-[2-[(1-Iminoethyl)amino]ethyl]-2-methyl-L-cysteine maleate form II crystalline salt | BROSTROM LYLE (US) | 2004-10-21 | — | — | US | disclosed |
| US-20040209956-A1 | S-[2-[(1-Iminoethyl)amino]ethyl]-2-methyl-L-cysteine maleate form II crystalline salt | BROSTROM LYLE (US) | 2004-10-21 | — | — | US | disclosed |
| US-20040204488-A1 | S-[2-[(1-Iminoethyl)amino]ethyl]-2-methyl-L-cysteine maleate crystalline salt | PHARMACIA CORPORATION | 2004-10-14 | — | — | US | disclosed |
| US-20040204488-A1 | S-[2-[(1-Iminoethyl)amino]ethyl]-2-methyl-L-cysteine maleate crystalline salt | PHARMACIA CORPORATION | 2004-10-14 | — | — | US | disclosed |
| WO-2004080955-A1 | S-[2-[1-IMINOETHYL)AMINO]ETHYL]-2-METHYL-L-CYSTEINE MALEATE CRYSTALLINE SALT | PHARMACIA CORPORATION (US) | 2004-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040204488-A1 | S-[2-[(1-Iminoethyl)amino]ethyl]-2-methyl-L-cysteine maleate crystalline salt | SLC7A1, CTH, BHMT2 | TSHR 4039/4885NOS3 825/4885NOS1 894/4885 |
| US-20040209956-A1 | S-[2-[(1-Iminoethyl)amino]ethyl]-2-methyl-L-cysteine maleate form II crystalline salt | CLCN2, CLIC1, CLIC4 | TSHR 4791/4885NOS3 3207/4885NOS1 3546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.